IBCC chapter & cast- Immune-related adverse events from checkpoint inhibitors

If you haven't started seeing these yet, you will soon. Checkpoint inhibitors are a form of immunotherapy being used for an increasingly broad range of malignancies. They cause a diverse range of adverse events, due to releasing uncontrolled autoimmune hyperactivity. Clinically this can mimic just about any rheumatologic condition. Fortunately these events are quite treatable. However, a high index of suspicion and prompt therapy is important.

This is a new field under explosive development. The chapter will be updated as new studies becomes available (if you find new information that should be included, please alert me in the comments section below). Each sub-section in this chapter is hyperlinked to the American Society of Clinical Oncology 2018 guidelines, currently the single best source for this information.